The Reverse Merger Wire

Halter Financial Group, an active reverse merger consulting firm, was granted a U.S. federal registration for the service mark "APO."

An alternative public offering, or APO, is commonly used market nomenclature for a shell merger followed by a private placement.

Source: Press Release

Redwood Capital, a subsidiary of S3 Investment Co. that assists companies with reverse mergers, will help Chinese chemical company Shandong Yiteng Chemical Co. go public in the U.S.

Redwood Capital said in a statement that it now has three active reverse merger clients in China and is considering several additional candidates.

Source: Press Release

Mid-Continental Securities Corp. sold control of Hong Kong-based shell company Studio II Productions for $200,000 to the chief executive of a Hong Kong-based furniture company.

Cheung Ming acquired about 6.63 million shares in the shell, for a 88.5% stake. Mid-Continental supplied some of the funds to Ming in the purchase.

Ming is CEO of Hengli & Liqi Furniture.
Filing: SC14F-1

Angstrom Technologies Corp., a Boston-based computer technology company, said it completed a reverse merger March 27 with shell company Sanford Exploration.

Angstrom says it specializes in "green" computing, providing blade servers and workstations to datacenters that use novel cooling techniques to reduce energy usage. It has had $50 million in revenues since inception in 2000, the company said.

The combined company plans to change its name to Angstrom Microsystems Corp.

Its Bulletin Board stock closed at $1.55 on April 18.
Filing: 8-K

A drug company that became public through a 2006 reverse merger raised $5.3 million in a recent private placement.

San Francisco-based Osteologix sold 4 million shares for $1.32 each to investors including Nordic Biotech Advisors and Burlingame Equity Investors. Punk Ziegel & Co. acted as placement agent.

Osteologix shares last closed on April 14 at $1.05.

The company, which is developing drugs to treat and prevent bone and joint tissue diseases, has raised more than $20 million in three private placements since its reverse merger with shell Castle & Morgan Holdings in May 2006. Its lead drug candidate is designed to treat osteoporosis.

Nordic has invested in all of the company's placements since that time. Other investors have included Bristol Capital Advisors, Nite Capital, and Goldman Sachs Group.
Filing: 8-K

MPM Asset Management, a Boston-based venture capital company focused on life sciences, recently created a Form-10 shell company with the assistance of the New York law firm of Feldman Weinstein & Smith.

The shell, called MPM Acquisition Corp., has 5 million shares outstanding. They are controlled by Steven St. Peter, MPM Acquisition's president and a general partner at MPM Asset Management, and Ansbert Gadicke, also an MPM general partner.
Filing: 10-12G

Yongye Biotechnology International, a Chinese distributor of plant and animal nutrients, completed a reverse merger with the shell company Golden Tan Inc. Yongye also sold 6.5 million shares for $1.54 each to raise $10 million in a private placement.

Roth Capital Partners acted as placement agent.

Yongye's shares traded at $2.25 on April 21.

The company develops, produces, and sells fulvic acid-based liquid and powder nutrient compounds that are used in agriculture.

Yongye's deal included a "make good" provision, a standard feature in Chinese reverse mergers. If Yongye fails to achieve $10.3 million in net income in its 2008 fiscal year, the purchasing shareholders will receive 2 million shares from the original shareholder for no additional consideration.

Source: Press Release